Clinical trials
Chemoradiotherapy clinical trials
Below are recruiting chemoradiotherapy clinical trials, each written for real people, not researchers. We’re tracking 236 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07458529RecruitingPhase 2
Chemoradiation plus immunotherapy with or without probiotics for rectal cancer
This trial tests adding an immunotherapy drug (tislelizumab) and a probiotic to standard chemoradiation for locally advanced rectal cancer that has not spread. The goal is to see if the probiotic helps the treatment work better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07478731RecruitingPhase 2
Combination therapy for advanced rectal cancer before surgery
This trial tests a new drug called SHR-1701 combined with standard chemotherapy and radiation for people with locally advanced rectal cancer. The goal is to shrink the tumor before surgery, making it easier to remove completely.
Wuhan, HubeiAges 18–75 - NCT07493928Recruiting
HPV testing after chemoradiation for cervical cancer
This trial checks if HPV is still present after standard radiation and chemo for cervical cancer. It may help see how well the treatment worked.
PragueAges 18 years+ - NCT07511725RecruitingPhase 2
Thiotepa spinal injection to prevent glioblastoma spread
This trial tests whether injecting a chemotherapy drug called thiotepa into the fluid around the brain and spine can prevent glioblastoma from spreading in patients whose tumor touches the fluid-filled spaces or who had a leak during surgery.
Hangzhou, ZhejiangAges 18–75 - NCT07530094RecruitingPhase 2
Radiation and chemotherapy with immunotherapy for advanced esophageal cancer
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT07555678RecruitingPhase 2
Chemotherapy, radiation, and immunotherapy for anal cancer
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07559045RecruitingPhase 2
Chemo-Immunotherapy Plus Radiation vs Standard Treatment for Advanced Esophageal Cancer
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
Zunyi, GuizhouAges 18–75 - NCT07595770RecruitingPhase 2
New immunotherapy combined with chemotherapy and radiation for esophageal cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07618078Recruiting
Personalized Cancer Risk Assessment for Nasopharyngeal Cancer
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
Beijing, Beijing MunicipalityAges 18–75 - NCT07636824RecruitingPhase 2
Chemotherapy plus radiation after bile duct cancer surgery
This study tests whether combining chemotherapy and radiation therapy after surgery improves outcomes for patients with bile duct or gallbladder cancer. It's designed for patients whose surgery showed signs the cancer might come back.
BeijingAges 18–80 - NCT07669220RecruitingPhase 2
Short radiation, immunotherapy, and chemo for advanced rectal cancer
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
GuangzhouAges 18–75 - NCT07371247Enrolling by invitationEarly Phase 1
Adjuvant treatment guided by ctDNA after chemoradiation for esophageal cancer
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
Nanjing, JiangsuAges 18–80 - NCT07130149Enrolling by invitationPhase 2
Sonodynamic therapy plus chemoradiation for glioblastoma
This trial combines a new therapy (sonodynamic therapy) with standard radiation and chemotherapy for glioblastoma. It aims to see if this approach is safe and how well it works for people who have just been diagnosed and had surgery.
Zhengzhou, HenanAges Up to 75 years - NCT07016737Enrolling by invitationPhase 3
Chemotherapy and radiation for returning esophageal cancer
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
Nanjing, JiangsuAges 18 years+ - NCT06990178Enrolling by invitation
Adaptive Neoadjuvant Therapy for Esophageal Cancer
This trial is testing a new treatment approach for esophageal cancer that includes chemotherapy and immunotherapy before surgery. The goal is to see if this combination can help shrink the tumor and improve outcomes.
Shenzhen, GuangdongAges 18–75 - NCT06863831Enrolling by invitation
Comparing YSQTG to placebo with standard treatment for esophageal cancer
This trial tests whether adding an herbal granule (YSQTG) to standard chemotherapy with or without immunotherapy helps patients with a specific type of advanced esophageal cancer. It focuses on people whose cancer is stage III to IVa and who have not had treatment yet.
Beijing, ChaoyangAges 18–80 - NCT06786780Enrolling by invitationPhase 2
Predicting chemoradiation response with cervical cancer organoids
This trial is studying whether lab-grown mini-tumors (called organoids) from your cervical cancer biopsy can predict how well chemoradiation will work. It aims to create a tool to help doctors choose the best treatment for each patient.
Chongqing, ChinaAges 18 years+ - NCT06747832Enrolling by invitationEarly Phase 1
INK cells after chemoradiation for small cell lung cancer
This trial tests whether adding a special immune cell called iNK cells after standard chemoradiation can help keep small cell lung cancer from coming back.
Weifang, Shandong Province, China.Ages 18–75 - NCT06303583Enrolling by invitationPhase 1/Phase 2
Chemo-radiation followed by immunotherapy for esophageal cancer
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
Hangzhou, ZhejiangAges 18–75 - NCT06048926Enrolling by invitation
Carrelizumab with chemoradiation for advanced esophageal cancer
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
NanjingAges 18–75
Hear when a new Chemoradiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chemoradiotherapy?
- Yes. Clin2 currently lists 236 recruiting chemoradiotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chemoradiotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chemoradiotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.